Improving Outcome in Ischemia and Ischemia Reperfusion Injury Using Elemental Reducing Agents
Abstract
Many injuries and diseases cause inadequate tissue blood supply resulting in low oxygen levels that are insufficient to maintain normal life processes. Treatment for this phenomenon (ischemia) is almost always designed to restore normal blood flow (reperfusion). Both ischemia and ischemia followed by reperfusion increase oxidative damage to cells and are associated with term functional damage to tissues. We have found that anions of a group of adjoining elements in the periodic table of the elements, bromide, iodide, selenide and sulfide, improve outcome in preclinical animal models of myocardial ischemia and reperfusion injury as well as chronic heart failure in mice. We refer to these anions as Elemental Reducing Agents (ERAs) because they act as electron donors in oxidation and reduction reactions in vivo. These and other results described in detail in the following technical volume, suggest ERAs can be used to improve outcome in many injuries and diseases that cause oxidative damage due to ischemia and reperfusion. Therefore, we propose to: 1. Determine whether iodide improves outcome in a pig model of chronic heart failure. 2. Measure iodide levels in plasma samples from civilian trauma cases to learn if there is a relationship between iodide and outcome, and more rigorously define the relationship between plasma levels of iodide and outcome in animals. 3. Define the mechanism of action of ERAs. 4. Further test the hypothesis that ERAs enhance the transplantability of tissue. The development of ERA technology represents a very real opportunity to improve treatment of both civilian and combat patients suffering from trauma, blood loss, and disease.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- May 07, 2018
- Source ID
- W911NF1710360
Entities
People
- Mark Roth
Organizations
- Army Contracting Command
- Fred Hutchinson Cancer Center
- United States Army